The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Capsules, Oral, 2mg, Once daily, 1 year
Capsules, Oral, 15mg, Once daily, 1 year
Capsules, Oral, 0mg, Once daily, 1 year
The effect of BMS-823778 versus placebo on carotids and/or ascending aortic will be measured by fluorodeoxyglucose (FDG) uptake in the index vessel as by positron emission tomography (PET) imaging
Time frame: Day 168
Structural changes in the arterial wall (absolute, percent change, and both, from baseline in four indices)
Structural changes in the arterial wall (absolute, percent change, and both, from baseline in four indices): total vessel area, wall area, wall thickness, and wall area/total vessel area ratio (normalized wall index), based on the average of the right and left carotids, measured by Magnetic Resonance Imaging (MRI)
Time frame: Day 364
Safety will be measured by adverse event, vital signs, electrocardiogram, physical examinations, clinical laboratory tests and Ferriman- Gallwey scores
Time frame: Approximately up to 60 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.